GlassScriptPhysician profile
Adam C Shepard
NPI 1437511326
$1,313.09
in general payments reported to CMS, 2019-2025
17 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $214 · 2021: $219 · 2022: $266 · 2023: $167 · 2024: $103 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.95 | 2020-2025 | Lokelma, Farxiga |
| Amgen INC. | $181.17 | 2020-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $151.44 | 2020-2023 | Jynarque |
| Fresenius USA Marketing, INC. | $148.61 | 2020-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $97.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.90 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $63.27 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $49.34 | 2023-2025 | Veltassa |
| Nxstage Medical, INC. | $46.42 | 2021 | |
| Novo Nordisk INC | $41.75 | 2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $31.52 | 2024 | |
| Mallinckrodt Hospital Products INC. | $31.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.40 | 2023 | Jardiance |
| Cormedix INC. | $23.00 | 2024 | Defencath |
| Akebia Therapeutics INC | $20.23 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $17.99 | 2025 | |
| Glaxosmithkline, LLC. | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.